UCLA researchers in the Division of Digestive Disease in the Department of Medicine at the David Geffen School of Medicine, led by Drs. Charalabos Pothoulakis and Dimitrios Iliopoulos, have identified several biomolecules that are potential diagnostic markers for ulcerative colitis. These markers can be used singularly or combined, depending on the diagnostic testing need. There is increased flexibility for testing as a positive correlation is related to increased marker levels or the presence of the molecule, depending on the biomarker. Researchers have also identified a marker that can distinguish ulcerative colitis from Crohn’s Disease.
Diagnosing the severity of ulcerative colitis (UC) and determining a patient’s risk for developing colitis-associated colon cancer has been challenging due to the lack of specific biomarkers. Many biomarkers for inflammatory bowel diseases are not highly specific to just UC, but are also biomarkers for Crohn’s Disease and many other gastrointestinal diseases. The identification of a biomarker that is specific to UC will be highly useful to develop of diagnostic and prognostic tests.
References: UCLA Cases 2013-778, 2013-787, 2013-401, 2014-284, 2015-113, 2015-276, 2015-851
Pothoulakis Group: http://gastro.ucla.edu/body.cfm?id=131
Iliopoulos Group: http://gastro.ucla.edu/body.cfm?id=157
Additional technologies available from the Pothoulakis group: http://bit.ly/1WXT3Q6
Additional technologies available from the Iliopoulos group: http://bit.ly/1OPohUU
For further information on this innovation, contact:Rick Clark